open access

Vol 8, No 11 (2007): Practical Diabetology
Original articles (submitted)
Published online: 2008-02-04
Get Citation

Interleukin 12 - next essential link between diabetes type 2 and atherosclerosis

Małgorzata Wegner, Marzena Dworacka, Hanna Winiarska
Diabetologia Praktyczna 2007;8(11):425-430.

open access

Vol 8, No 11 (2007): Practical Diabetology
Original articles (submitted)
Published online: 2008-02-04

Abstract

BACKGROUND. Interleukin 12 (IL-12) is the evidently proatherogenic cytokine acting throughout several different mechanisms. High serum IL-12 levels were found before in patients with coronary artery disease, while little is known about this cytokine in type 2 diabetic patients. We aimed to evaluate IL-12 serum concentration in patients with diabetes type 2 together with factors related to the pathogenesis of this disease.
MATERIAL AND METHODS. We studied 31 patients with diabetes type 2 treated with gliclazide and 19 healthy individuals. Fasting glycaemia, glycated hemoglobin (HbA1c), 1,5-anhydro-D-glucitol (1,5-AG) plasma level, lipid profile, C-peptide, insulin and IL-12 concentrations in serum were estimated. Homeostasis Model Assessment of Insulin Resistance (HOMAIR index) was calculated as well. RESULTS. There was an increase in IL-12 serum level in patients with diabetes type 2 in comparison to healthy group. Serum IL-12 level was positively correlated with body mass index (BMI), C-peptide, insulin and HOMAIR. It was also found the negative correlation between IL-12 serum level and high density lipoprotein (HDL). The multivariate regression analysis revealed that IL-12 concentration in serum is independently determined by BMI.
CONCLUSIONS. These data revealed higher levels of the IL-12 in serum of diabetic patients than in healthy individuals. These high, potentially proatherogenic, serum IL-12 levels are influenced simultaneously by several factors including b-cells dysfunction, peripheral insulin resistance, low HDL levels and obesity. Nevertheless, it seems to be likely that the most evident decrease in IL-12 serum levels in diabetic patients could be achieved by body mass reduction.

Abstract

BACKGROUND. Interleukin 12 (IL-12) is the evidently proatherogenic cytokine acting throughout several different mechanisms. High serum IL-12 levels were found before in patients with coronary artery disease, while little is known about this cytokine in type 2 diabetic patients. We aimed to evaluate IL-12 serum concentration in patients with diabetes type 2 together with factors related to the pathogenesis of this disease.
MATERIAL AND METHODS. We studied 31 patients with diabetes type 2 treated with gliclazide and 19 healthy individuals. Fasting glycaemia, glycated hemoglobin (HbA1c), 1,5-anhydro-D-glucitol (1,5-AG) plasma level, lipid profile, C-peptide, insulin and IL-12 concentrations in serum were estimated. Homeostasis Model Assessment of Insulin Resistance (HOMAIR index) was calculated as well. RESULTS. There was an increase in IL-12 serum level in patients with diabetes type 2 in comparison to healthy group. Serum IL-12 level was positively correlated with body mass index (BMI), C-peptide, insulin and HOMAIR. It was also found the negative correlation between IL-12 serum level and high density lipoprotein (HDL). The multivariate regression analysis revealed that IL-12 concentration in serum is independently determined by BMI.
CONCLUSIONS. These data revealed higher levels of the IL-12 in serum of diabetic patients than in healthy individuals. These high, potentially proatherogenic, serum IL-12 levels are influenced simultaneously by several factors including b-cells dysfunction, peripheral insulin resistance, low HDL levels and obesity. Nevertheless, it seems to be likely that the most evident decrease in IL-12 serum levels in diabetic patients could be achieved by body mass reduction.
Get Citation

Keywords

interleukin 12; diabetes type 2; atherosclerosis

About this article
Title

Interleukin 12 - next essential link between diabetes type 2 and atherosclerosis

Journal

Clinical Diabetology

Issue

Vol 8, No 11 (2007): Practical Diabetology

Pages

425-430

Published online

2008-02-04

Bibliographic record

Diabetologia Praktyczna 2007;8(11):425-430.

Keywords

interleukin 12
diabetes type 2
atherosclerosis

Authors

Małgorzata Wegner
Marzena Dworacka
Hanna Winiarska

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

 

Wydawcą serwisu jest  "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl